Northstar Neuroscience Huddles to Consider Unsolicited Takeover Bid
Northstar Neuroscience is in one tight spot. The Seattle-based medical device company’s lead product candidate for stroke patients failed in clinical trials on Jan. 22, and 83 percent of its stock value (NASDAQ: NSTR) evaporated in a ...